Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622141 | 0.87 | RYR2 (0.55) | RYR2KCNH2KDM4EALDH1A1CASP1 | |
| SCHEMBL6866663 | 0.80 | RYR2 (0.46) | RYR2 | |
| SCHEMBL12894396 | 0.79 | RYR2 (0.43) | RYR2KCNH2 | |
| SCHEMBL15935968 | 0.79 | HTR1A (0.55) | RYR2ALDH1A1MAPTKMT2A | |
| SCHEMBL6867057 | 0.78 | RYR2 (0.51) | RYR2KCNH2MEN1KMT2A | |
| SCHEMBL15047107 | 0.78 | RYR2 (0.45) | RYR2KDM4EMAPT | |
| SCHEMBL15936312 | 0.78 | RYR2 (0.51) | RYR2KCNH2KDM4ENOTUMDRD4 | |
| SCHEMBL9636604 | 0.78 | RYR2 (0.54) | RYR2KCNH2ALDH1A1NOTUM | |
| SCHEMBL3428843 | 0.77 | RYR2 (0.67) | RYR2 | |
| SCHEMBL14862467 | 0.77 | RYR2 (0.50) | RYR2KCNH2KDM4EALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928850-B1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | UNIV COLUMBIA (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | RYR2 275/4885KCNH2 19/4885KDM4E 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.